Empagliflozin (Jardiance)

Jardiance, INN-Empagliflozin

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance®), ameliorates glucotoxicity via excretion of excess glucose in urine (glucosuria) and significantly improves cardiovascular mortality in ...

Empagliflozin: Novel antidiabetes and pro-cardiac drug

Empagliflozin has been shown to improve glycaemic control and reduce CV mortality along with salutary effects on renal outcomes as compared to placebo in a recently conducted EMPA-REG OUTCOME trial in a large number of patients.[1,2] In this study, more than 7000 patients were randomly assigned to receive empagliflozin in the dose of 10 mg or 25 mg or placebo once daily. Patients were followed ...

Empagliflozin and the Prevention of Heart€Failure

SEE PAGE 347 H eart failure develops in more than 1 in 5 patients with diabetes mellitus (DM) older than 65 years of age and augers an extremely poor prognosis, with a median survival of approximately 4 years. The landmark EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) showed that empagliflozin significantly reduced the primary composite...

Impact of empagliflozin on diabetic kidney disease

Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule-glomerular feedback, thereby protect against diabetes-induced caidio-renal injuries.